NORMAN, OK – In a significant leap forward for cancer research, scientists at the University of Oklahoma...
Endeavor BioMedicines announces pivotal Phase IIb WHISTLE-PF trial results, demonstrating taladegib’s potential to redefine IPF treatment by...
By Douglas Feil, NBCF Chief Program Officer In recent years, glucagon-like peptide-1 (GLP-1) medications have surged in...
NEW YORK, NY — As the world enters the mid-point of Breast Cancer Awareness Month, a global...
NEW YORK CITY – In a powerful demonstration of the intersection between public advocacy and scientific rigor,...
OTTAWA – A landmark national survey released by Breast Cancer Canada has revealed a profound public demand...
AMMAN, Jordan — The World Health Organization (WHO) Director-General, Dr. Tedros Adhanom Ghebreyesus, has concluded the opening...
This is the latest installment in a new series where BioPharma Dive uses data visualization to recap...
In the rapidly evolving landscape of medical technology, a significant breakthrough has emerged in the fight against...
For decades, the standard workflow in preclinical toxicology remained stubbornly static: a pathologist would peer through a...
